Thromboembolic complications in adult congenital heart disease: the knowns and the unknowns

Clin Res Cardiol. 2021 Sep;110(9):1380-1391. doi: 10.1007/s00392-020-01746-2. Epub 2020 Oct 9.

Abstract

Despite impressive improvement in long-term survival, adults with congenital heart disease (CHD) remain exposed to a significant cardiovascular morbidity over lifetime. Thromboembolic events (TE) are a major issue. Specific anatomic groups have been shown a particular high risk of TE, including cyanotic heart disease and Fontan circulation. Many intercurrent clinical factors add a substantial risk such as intracardiac medical devices, atrial arrhythmia, endocarditis, or pregnancy. Nevertheless, what is unknown exceeds what is known, especially regarding the management of this heterogenous patient population. Anticoagulation decision should always be individualized weighing balanced with the alternative risk of hemorrhagic complications. In this review, we aim to synthetize existing literature on TE in adults with CHD, discuss management issues, highlight gaps in knowledge, and intend to suggest high priority research.

Keywords: Congenital heart disease; Management; Stroke; Thromboembolic events.

Publication types

  • Review

MeSH terms

  • Adult
  • Anticoagulants / administration & dosage*
  • Anticoagulants / adverse effects
  • Heart Defects, Congenital / complications*
  • Heart Defects, Congenital / physiopathology
  • Hemorrhage / chemically induced
  • Humans
  • Risk Factors
  • Thromboembolism / etiology*
  • Thromboembolism / therapy

Substances

  • Anticoagulants